endogenous glp 1 production Synthesis, secretion, and metabolism of glucagon-like peptide (GLP-1) The Interplay Between GLP-1-Based Therapies,

Regular follow-up appointments are necessary to monitor glycemic control (hemoglobin A1c typically every 3 months initially), weight changes, cardiovascular parameters, and renal function

GLP-1s likely improve those numbers, though the formal trial hasnt been done

GLP1 agonist treatment improves glycaemia, aids weight loss, improves cardiovascular, renal and limb outcomes, and leads to a reduction in allcause mortality in type 2 diabetes (Kristensen et al., 2019

At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable

Major metabolites identified are trimethylamine oxide in urine and gamma-butyrobetaine in feces

Med.Sci Monit